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QUESTION AND ANSWER Open Access
Video Q&A: Rapid urine LAM test for
HIV-associated TB - potential to reduce deaths?
An interview with Stephen Lawn
Stephen D Lawn1,2
Abstract
In this video Q&A, we talk to Dr Stephen Lawn about the point-of-care LAM test for HIV-associated TB, which has
the potential to save lives by improving rapid diagnosis and treatment.
Introduction
Stephen Lawn trained in medicine at Nottingham
University and specialised in Infectious Diseases in
London in the UK. At various stages of his career as a clin-
ician scientist, he has worked in Ghana in West Africa, the
Centers for Diseases Control and Prevention in Atlanta,
USA, and at the University of Cape Town in South Africa.
He is a Reader and Consultant Physician in Infectious
Diseases at the London School of Hygiene & Tropical
Medicine and an Associate Professor of Infectious Diseases
and HIV Medicine at the University of Cape Town. His
major research interests are in HIV infection and tubercu-
losis (TB). In Cape Town, he has conducted studies evaluat-
ing novel assays and approaches to screening and diagnosis
of HIV-associated TB.
Stephen Lawn has no conflicts of interest to declare in
relation to any of the diagnostic tests referred to in this
article.
Transcript
1. What is the scale of the global HIV-associated
tuberculosis (TB) epidemic?
The World Health Organization estimated that in 2011
there were 1.1 million new or recurrent cases of TB in
people living with HIV worldwide, which is around 13% of
total TB cases. This burden of HIV-associated TB is highly
concentrated in the countries of sub-Saharan Africa, which
account for 79% of all cases. Disease rates are highest in
countries towards the south of the continent where HIV
prevalence is greatest. Here between 50% and 80% of TB
cases are HIV-co infected. One country alone, South Africa,
accounts for almost 30% of all cases worldwide. Outside
Africa, TB is also a common opportunistic infection in
people living with HIV in south-east Asia and South
America and among HIV-infected injection drug users in
the countries of eastern Europe and central Asia.
HIV-associated TB causes approx 430,000 deaths per
year, although these are classified as HIV deaths in the
International Classification of Diseases. Approximately
one third of people who die with TB are HIV-co infected
and approximately 25% of global HIV/AIDS deaths have
TB as the underlying cause. So, TB is the leading cause
of death in people with HIV/AIDS worldwide.
2. Why is diagnosis of TB more challenging in people
living with HIV infection, especially in resource-limited
settings?
Diagnosis of TB in resource-limited settings relies heavily
on sputum smear microscopy and chest radiology, both of
which are impaired in people with HIV co infection. TB
diagnosis by sputum smear microscopy depends on the
release of TB bacilli (Mycobacterium tuberculosis) in suffi-
cient numbers into the sputum such that the concentra-
tion of organisms exceeds 10,000 bacilli per ml of sputum,
which is the limit of detection of the assay. However,
HIV impairs antimycobacterial immune responses so that
Correspondence: stevelawn@yahoo.co.uk
1Department of Clinical Research, Faculty of Infectious and Tropical
Diseases, London School of Hygiene and Tropical Medicine, Keppel Street,
London WC1E 7HT, UK
2Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular
Medicine, University of Cape Town, Cape Town, South Africa
© 2013 Lawn; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Lawn BMC Medicine 2013, 11:158
http://www.biomedcentral.com/1741-7015/11/158
co-infected patients have reduced immunopathology in
the lungs, which means that there is less inflammation
and less lung tissue damage. As a result, lower concentra-
tions of bacilli are liberated into sputum and so sputum
smears are much more likely to be negative. This issue is
further compounded by the fact that when patients have
advanced disease and are very weak, it can be very difficult
for them to expectorate good quality sputum samples.
In addition to sputum smear microscopy, chest radi-
ology is less useful in those with HIV co infection. Again,
because of reduced immunopathology, the chest radio-
graphic appearances are often non-specific and lack
the typical characteristics of pulmonary TB seen in
HIV-negative patients. HIV co-infection also increases
the frequency of extra-pulmonary disease which further
compounds the challenge of diagnosis.
The huge challenge of diagnosis of HIV-associated TB
is graphically illustrated by a number of post-mortem
studies of patients with HIV/AIDS who have died in
hospitals in sub-Saharan Africa. These studies have re-
peatedly shown that between 30% and 50% of patients
had evidence of TB, much of which is disseminated and
remained undiagnosed at the time of death.
3. What other laboratory tests may help improve
diagnosis of HIV-associated TB?
Mycobacterial culture of samples, especially in liquid
media, is the assay with the highest sensitivity for TB
diagnosis. However, this is slow, often yielding results in
weeks rather than days. It is technologically demanding
and expensive and is only feasible in centralised labora-
tories. For these reasons it is not generally available in
many resource-limited settings.
However, a real landmark development is the Xpert
MTB/RIF assay which was endorsed by WHO in
December 2010. This is a simplified fully automated
real-time PCR assay system that is cartridge-based and
requires very limited training for operation. It takes
just two hours to generate a result and it has much
higher sensitivity that sputum smear microscopy. A
single test can detect all smear-positive cases and ap-
proximately 70%-75% of smear-negative cases. How-
ever, there are a number of draw-backs. The hardware is
sophisticated and expensive. Each cartridge, even at heavily
subsidized prices, costs $10. Moreover, its use will largely
be confined to laboratory settings as it is difficult to imple-
ment at the point-of-care. When use is laboratory-based,
results cannot be used to immediately inform treatment
decisions.
What is really needed is a low-cost point-of-care assay
that can be used to reliably diagnose TB and permit TB
treatment to be started at the same clinic visit. The
Determine TB-LAM assay is one such test that has re-
cently become commercially available. Although this has
not yet been endorsed and more evidence is needed
from ongoing studies, this assay has real potential to
play a useful role in diagnosis of HIV-associated TB.
4. What is the basis for TB diagnosis using the urine
lipoarabinomannan (LAM) antigen detection?
Lipoarabinomannan (LAM) is a glycolipid component of
the cell wall of Mycobacterium tuberculosis. It is pro-
duced in large quantities by the organism and this may
relate to the fact that it is immunomodulatory, favouring
survival of the organism in the human host. LAM can
be detected in the urine of a proportion of patients with
TB, even if the primary focus of the disease is, for ex-
ample, pulmonary. LAM is thought to gain entry to the
urine either via the bloodstream or via direct involve-
ment of the renal tract by TB in those with disseminated
disease. Regardless of the mechanism, detection of LAM
in urine can be used as a means of TB diagnosis.
TB diagnosis via detection of LAM in urine can be
done in the laboratory using a simple polyclonal antibody
sandwich ELISA and the initial diagnostic accuracy studies
were done using this format of the assay. The ELISA has
now been developed into a simple lateral-flow ‘strip-test’
format – which is an immunochromatographic assay that
looks like a urine pregnancy test.
The test requires a fresh urine sample and just 60 μL
is applied to the sample pad at the bottom of the strip
without any prior processing required. The strip is left
for 25 minutes during which time the urine containing
LAM travels up the test strip and immobilised capture
and detection antibodies labelled with colloidal gold lead
to the development of a purple band in the test window.
If the band is of sufficient intensity when compared with
a reference card, it is scored as a positive test for LAM.
5. In which patients is the urine LAM test useful?
A series of studies published since 2009 have shown that
the utility of LAM detection for TB diagnosis is re-
stricted to patients with HIV infection and advanced im-
munodeficiency. It is not useful in HIV-negative patients
and it is not useful in HIV-positive patients with CD4
counts >200 cells/μL. So this test should not be applied
to unselected patients.
However, among HIV-infected patients with CD4
counts <200 cells/μL the test is useful. The lower the
CD4 cell counts and the sicker the patients (as defined
by a range of characteristics), the greater the sensitivity
for TB diagnosis. The likely reason for this is that such
patients have a much higher risk of disseminated disease
and therefore a greater likelihood of LAM being present
in urine.
The sensitivity of the assay entirely depends on the
particular characteristics of the patients tested. Among
ambulatory out-patients with CD4 cell counts <50 cells/μL,
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the test detects approximately two-thirds of cases. Among
in-patients who are of course sicker, this proportion may be
higher. Conversely, among ambulatory patients with higher
CD4 counts, the sensitivity will be lower.
6. What are the advantages and disadvantages of this
test?
The major advantages of this test are obvious. The test
is low-cost (currently marketed at $3.50 per test), rapid,
and doesn’t require any equipment. Urine is easy to
obtain even among sick patients in hospital who may
find it difficult to produce sputum samples. Urine is safe
and easy to handle and testing could readily be done by
nursing staff following limited training. Most import-
antly, it can be used at the point-of-care, permitting
diagnosis and start of treatment at a single clinic visit,
potentially reducing treatment delays greatly.
The disadvantages of the test are that it should only be
used among those who are confirmed to be HIV-
infected and to have advanced immunodeficiency as de-
fined by CD4 count or WHO clinical staging. The sensi-
tivity of the assay is limited and so it can only be used as
a test to diagnose TB but cannot be used as a test to
rule-out TB. While several well-conducted studies of
LAM ELISA and point-of-care assays have found very
high assay specificity, some studies have found more
limited specificity. Whether this is true or an artefact of
study design remains to be fully clarified. Finally, the op-
timal cut-off for scoring the point-of-care strip tests as
positive or negative has yet to be finalised. This needs to
take into account both its ease of use by health-care
workers as well as diagnostic accuracy.
So a range of further studies are needed to clarify the
use of the Determine TB-LAM point-of-care assay.
These must increase the evidence base on the diagnos-
tic accuracy of this assay, operational research is
needed on its use in the clinical rather than the labora-
tory environment and finally, large-scale studies are
needed to assess the impact of implementation on clin-
ical outcomes.
7. What role might this assay play in diagnosis of
HIV-associated TB in resource-limited settings?
There are several characteristics of the Determine TB-
LAM point-of-care assay that makes it potentially very
useful. First, the really key observation is that although
the sensitivity of the assay is somewhat limited, sensitiv-
ity is highest in the very sub-set of patients who have
the worst prognostic characteristics and are at greatest
risk of death. Secondly, the assay permits TB diagnosis
during a single clinic visit and immediate initiation of
treatment. So there is the real potential to accelerate diag-
nosis and treatment and thereby reduce mortality risk.
The assay is not a stand-alone assay but should be
used in combination with other assays. Indeed, there is
incremental sensitivity when used in combination with
sputum smear microscopy or sputum Xpert testing.
Thus, the LAM assay shortens the time to diagnosis in
the sickest patients and increases overall sensitivity when
used in combination with other assays. So this assay may
play an important role in the diagnostic algorithm.
There are two key clinical populations in which this
assay may come to play an important role. First, the
assay may be used to screen for TB in HIV-infected out-
patients with advanced immunodeficiency before they
start antiretroviral therapy. Second, it can be used for
screening and diagnosis of TB in HIV-infected in-
patients. By shortening the time to diagnosis in these
key patient groups, we would hope that their mortality
risk would be reduced. So the real goal and potential of
this assay is to reduce deaths from HIV-associated TB.
8. Where can I find out more?
See references [1-10].
Additional file
Additional file 1: An interview with Stephen Lawn.
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